NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova’s Psilocybin-based Therapeutics Showing Vast Potential for Autism and Other Neuroinflammatory Disorders”
Update on 4/8/2022 livestream discussing clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for Fragile X Syndrome, in the coming weeks.
NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) is developing treatment for autism based on psilocybin with fast track potential to commercialization. Multi-billion dollar revenue potential with off-label use. Most importantly: $NMLSF team has proven track record bringing drugs through FDA process to market, (and generating +10X-50X returns for investors).